US stocks showed mixed performance on Wednesday. The S&P 500 and Nasdaq hovered near record highs, supported by strong gains in big tech and chip stocks. However, hotter producer inflation increased pressure on the broader market. The Dow also faced downward pressure.
Index moves
The S&P 500 finished near an all-time high, supported by megacap technology and semiconductor stocks. Meanwhile, the Nasdaq outperformed, gaining ground as investors continued to favor AI and chip-related shares. In contrast, the Dow struggled as rising inflation concerns weighed on traditional blue-chip stocks. As a result, the major indexes reflected different investor reactions to the latest economic data.
Macro: hot PPI keeps the Fed in focus
The April Producer Price Index (PPI) came in hotter than expected, reinforcing the message from recent inflation reports. In particular, the wholesale price increase raised concerns that inflation may remain persistent. Consequently, investors became more cautious about the Federal Reserve’s ability to ease monetary policy soon.
Furthermore, Treasury yields climbed following the data, while the 10-year rate remained elevated. At the same time, the stronger-than-expected inflation reading suggested that borrowing costs could stay higher for longer. Therefore, investors continued to monitor upcoming economic reports for clearer signals about the Fed’s next policy move.
Sector and stock themes
Tech and semiconductor stocks once again led the market. Investors used the previous session’s inflation-driven selloff to increase exposure to AI, cloud, and leading chipmakers.
Companies tied to AI infrastructure, memory, and advanced logic rallied. Strong recent revenue trends across these sectors reinforced confidence in demand, despite higher discount rates.
In contrast, rate-sensitive and cyclical sectors underperformed. These included financials, small caps, and some traditional industrial stocks. Investors reassessed how persistent inflation and rising bond yields could affect profit margins and financing costs. Defensive sectors such as utilities and staples attracted selective interest as portfolio managers looked for ballast against ongoing macro volatility.
Bigger picture: markets climbing a familiar wall of worry
Despite inflation concerns, financial markets continued to show resilience. On one hand, megacap growth and chip companies benefited from strong demand and optimism surrounding AI infrastructure. On the other hand, persistent inflation and elevated borrowing costs remained significant risks. Nevertheless, the pullback in broader market weakness suggested that investors were still willing to support selected growth stocks.
For now, the biggest question remains whether technology leadership can continue to offset economic pressure. Ultimately, investors will be watching upcoming inflation data, Federal Reserve signals, and corporate earnings for clues about the market’s next direction.
VP Watchlist Updates
Below is an update on the VP Watchlist names for the week. In particular, the focus remains on recent catalysts, positioning, and notable developments that may influence future market trends.
Amwell® (NYSE: AMWL, $7.73)
Amwell® (NYSE: AMWL) is a leading provider of a SaaS-based, technology-enabled healthcare platform. The company announced its first-quarter financial results for the period ended March 31, 2026, on May 5.
“Entering 2026, Amwell’s main focus was to consolidate our platform. We aimed to fulfill the unmet needs of our Payer and Provider customers. Our Technology-Enabled Care infrastructure continues to gain traction. It addresses a gap in the market. Customers recognize its clear advantages, including lower costs, better outcomes, stronger market share, and greater control and agility.
“Our platform is performing well. It is also built to leverage the latest AI-powered innovations. This positions it as essential infrastructure for tech-enabled care delivery,” said Dr Ido Schoenberg, Chairman and CEO of Amwell.
“We are seeing powerful validation of the platform with significant pipeline growth and a number of meaningful renewals. With this momentum and the favorable regulatory tailwinds, Amwell is well-positioned for continued strong execution this year.
“We also remain focused on reaching our goal of positive cash flow from operations in the fourth quarter.”
FMC Corporation (NYSE: FMC, $12.73)
FMC Corporation (NYSE: FMC) reported its first-quarter 2026 results on April 29. The company exceeded its guidance, with Adjusted EBITDA above the high end of its range. It also reaffirmed its full-year outlook.
First-quarter revenue reached $759 million. This was a 4% decrease compared with the same quarter in 2025. Excluding India, revenue was $762 million, also down 4% year over year. The 2025 comparison included India.
On a GAAP basis, FMC reported a loss of $2.25 per diluted share. This was a decrease of $2.13 compared with the first quarter of 2025. The adjusted loss per diluted share was $0.23, down 41 cents year over year.
FMC Corporation also announced that its board of directors declared a regular quarterly dividend of 8 cents per share. The dividend is payable on July 16, 2026, to shareholders of record as of the close of business on June 30, 2026.
Eupraxia Reports New EREFS Data From RESOLVE Trial
Eupraxia Pharmaceuticals Inc. (EPRX) is a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology. The technology is designed to optimize local, controlled drug delivery for applications with significant unmet medical needs.
On May 5, the company announced the first Eosinophilic Esophagitis Endoscopic Reference Score (EREFS) data from the ongoing Phase 1b/2a portion of its RESOLVE trial. The trial is evaluating EP-104GI for the treatment of eosinophilic esophagitis (EoE).
These data were also presented at the ongoing Digestive Disease Week (DDW) conference in Chicago.
EP-104GI Shows Improvements in EREFS Outcomes
“The EREFS is an important, validated visual index of the severity of EoE disease in the esophagus of patients. It measures edema, rings and strictures, along with other visible markers of disease often associated with symptoms,” said Dr. James A. Helliwell, Chief Executive Officer of Eupraxia.
He added that the latest data demonstrated improvements in two key outcomes with EP-104GI. First, a full injection protocol of 20 injections resulted in more pronounced improvement than a protocol with fewer injections and less coverage area within the esophagus.
“Second, with the higher number of injections, a consistent response in both the inflammatory and fibrotic sub-scores of EREFS was observed,” Helliwell said.
He also noted that the EREFS data presented at DDW were consistent with improvements seen in EoE symptoms and tissue health (EoEHSS). The findings suggest improvements in inflammation, fibrosis and the associated narrowing of the esophagus.
Eupraxia Appoints Dr. Jeymi Tambiah as Chief Medical Officer
Eupraxia announced on Friday, May 1, the appointment of Dr. Jeymi Tambiah as Chief Medical Officer (CMO), alongside the retirement of its current CMO, Dr. Mark Kowalski.
Dr. Jeymi Tambiah (MB ChB, FRCS, MS, FAPCR, FFPM) is a board-certified cardiothoracic surgeon and physician-scientist. He practiced at Guy’s and St Thomas’ Hospitals before entering the biopharmaceutical industry in 2008.
Dr. Tambiah brings over 18 years of experience in clinical development, medical and regulatory strategy, and product commercialization across pharmaceutical and biotechnology organizations.
Eupraxia Hosts CEO Presentation and Q&A Webinar
Eupraxia recently co-hosted a CEO Presentation and Q&A Webinar with Tribe Public (www.TribePublic.com) on Wednesday, April 1. The event was titled “Turning EoE Into a Once-a-Year Appointment.”
The webinar featured James A. Helliwell, M.D., Co-founder and CEO of Eupraxia Pharmaceuticals (NASDAQ: EPRX). He discussed the company’s precision drug-delivery platform, its approach to eosinophilic esophagitis (EoE), and broader pipeline priorities.
The presentation was followed by a focused 5–10 minute Q&A session.
Watch the webinar on YouTube..
Modular Medical CEO Shares Growth Strategy and Investor Outlook
Modular Medical, Inc. (NASDAQ) develops innovative, patient-centric insulin delivery solutions. CEO Jeb Besser joined Tribe Public members on May 1 to discuss the company’s growth strategy. The discussion explored how an FDA-cleared device could serve the “almost-pumper” market. It focused on everyday users rather than just superusers.
Tribe Public hosted the CEO Presentation and Q&A webinar on Friday, May 1, 2026, at 8:00 a.m. PT / 11:00 a.m. ET. The session was titled “From FDA Wins to Scaling Manufacturing – What Investors Should Watch.”
The session lasted approximately 30 minutes. It began with a focused presentation, followed by a 5–10 minute live Q&A. Investors had the opportunity to ask about timelines, capital needs, and commercial strategy.
Besser’s formal remarks covered the webinar’s central theme. The discussion explored regulation, innovation, and recurring-revenue hardware.
Attendees who registered also joined Tribe Public’s membership base. This made them eligible for future invitations to CEO briefings, sector spotlights, and investor wish-list events.
Modular Medical Announces $3.4 Million Offering
On April 19, Modular Medical announced the pricing of a registered direct offering of 750,000 shares of the company’s common stock at $4.50 per share.
The company expects to receive approximately $3.4 million in gross proceeds before deducting placement agent fees and other offering expenses.
The offering was expected to close on or about April 21, 2026, subject to customary closing conditions.
FDA Clears Modular Medical’s Pivot Insulin Patch Pump
Modular Medical’s latest regulatory milestone strengthens its commercial outlook. On April 9, the company secured FDA 510(k) clearance for its Pivot tubeless insulin patch pump, moving the device from “launch-ready” to “launch-approved” in the growing diabetes market.
The FDA cleared the Pivot patch pump as a tubeless, removable insulin delivery system for commercial use in U.S. adults living with diabetes. This clearance formally validates the device’s design and performance.
The approval also converts the previously stated Q1 2026 launch, which was subject to an FDA response, into a tangible commercial pathway. It gives Modular Medical permission to enter an insulin pump market estimated at approximately $8 billion globally.
Pivot’s Design and Features
Pivot is designed as a simplified, two-part patch pump with a 3-milliliter removable reservoir. It does not require battery recharging and allows users to deliver a bolus without a dedicated controller.
The device aims to serve patients who have continued using multiple daily injections because traditional insulin pumps can feel too complex, cumbersome, or costly.
By clearing Pivot, the FDA has effectively endorsed Modular Medical’s effort to make advanced insulin delivery feel less like adopting a gadget and more like upgrading a daily habit.
- InterGroup Corporation delivered (Feb. 17) a notably stronger quarter, highlighted by a 20% jump in total revenue to $17.3 million and a 27% surge in hotel revenue as renovated rooms returned to service and travel demand improved. The company swung from a prior-year net loss to $1.0 million in net income, with operating income more than doubling to $2.0 million, underscoring better cost control and improved operating efficiency. Management further enhanced liquidity and sharpened strategic focus by selling a non-core 12‑unit Los Angeles multifamily property, generating a meaningful gain and additional working capital while maintaining stable performance across its real estate portfolio.
Volato Group, Inc. (SOAR) & M2i Global, Inc. (MTWO)
- Volato Group, Inc. (NYSE American: SOAR) today announced voting results indicate that the shareholders have approved the previously announced merger with M2i Global, Inc. (“M2i Global”)(OTCQB: MTWO) with 99% of the shares of common stock present or represented by valid proxy at the special meeting voting in favor of the merger. This marks a significant milestone toward closing the transaction and advancing Volato’s strategic expansion into the critical minerals sector. The number of shares of common stock present or represented by valid proxy at the special meeting was 15.1 million, representing approximately 40% of the total number of shares of common stock entitled to vote. Management believes that the approval reflects strong shareholder alignment with the Company’s strategic direction and long-term growth plans.
Nokia (NOK, $14.71, +11.69%)
- Nokia is quietly turning the humble home router into a mini network strategist, and Wall Street is starting to notice. NVIDIA’s billion-dollar bet on the Finnish vendor in 2025 further strengthened this narrative, connecting everyday home Wi-Fi with the emerging 6G and AI-native era.
- Nokia has introduced “agentic AI” for home and broadband networks, aiming to shift consumer connectivity from reactive troubleshooting to proactive, autonomous optimization. As a result, network management could become faster and more efficient.
- Instead of waiting for frustrated customers to reboot their routers, Nokia’s software monitors traffic patterns, anticipates congestion, and makes real-time adjustments. Consequently, streaming, gaming, and video calls can maintain a smoother experience.
- According to Nokia, agentic AI represents a new approach in which AI systems establish and pursue goals with limited or no human intervention. Rather than simply making one-time predictions, these systems continuously assess conditions and make decisions.
- In practical terms, this involves deploying fleets of micro-agents within broadband platforms such as Corteca and other access software. Each agent handles specific responsibilities, including fault isolation, congestion management, and quality-of-experience optimization.
NVIDIA (NVDA, $225.83, +2.29%)
NVIDIA will host a conference call on Wednesday, May 20, at 2 p.m. PT (5 p.m. ET) to discuss its financial results for the first quarter of fiscal year 2027, which ended April 26, 2026. The call will be webcast live (in listen-only mode) oninvestor.nvidia.com.
McDonald’s (MCD, $275.70, +.31%)
- Morgan Stanley (April 21) has adjusted its price target on McDonald’s (MCD) to $334, maintaining an Equal Weight stance on the stock. The firm’s analyst highlighted consumer strength heading into first-quarter results, noting that earnings quality will likely vary across the restaurant and food distribution landscape . While some operators may face headwinds, the underlying consumer backdrop remains robust, which could support McDonald’s performance as one of the industry’s quality players positioned to navigate the current environment .
Tesla (TSLA, $445.27, +2.73%)
Tesla’s latest reveal reads a bit like a family group chat gone public—over $500 million in revenue tied to Elon Musk’s own empire, because apparently vertical integration now includes your boss’s other companies. Meanwhile, the solar business is having a cloudy moment, robotics competition is heating up, and just to keep things interesting, Tesla snagged a jaw-dropping 370 Semi order. Oh, and in case that wasn’t enough, there’s talk of a casual $119 billion chip manufacturing push—because why not add semiconductors to the to-do list?
Serina Therapeutics (NYSE: SER, $1.56)
Serina Therapeutics (NYSE: SER) (www.serinatx.com) seems to have have just traded itself into Wall Street’s good graces, pairing fresh capital with a late-session pop that suggests investors are finally starting to connect the dots between polymer chemistry and portfolio returns. In Huntsville, Alabama, Serina Therapeutics announced definitive agreements for a private placement of common stock and pre-funded warrants that could bring in up to 30 million dollars in gross proceeds. The first 15 million dollar tranche is expected to close on March 20, 2026, with a second tranche of up to 15 million dollars anticipated by April 30, 2026, subject to customary closing conditions.
What makes the deal stand out in a biotech tape crowded with discounts is the pricing: the securities are being sold at about 2.25 dollars per share, a roughly 68 percent premium to Serina’s March 17 closing price, signaling that insiders are willing to pay up for exposure to the company’s clinical agenda. The financing also adds board-level heft, with director Greg Bailey, M.D., stepping into a Co-Chairman role as he leads the investment, a move that effectively puts the capital and the governance on the same optimistic page. Learn more here.
Intel (INTC, $120.29)
Intel’s latest rally is more than just another chip stock pop; it’s the market’s way of voting “yes” on a reshuffled AI and manufacturing order in which Intel (INTC), Apple (AAPL), and Nvidia (NVDA) are quietly rehearsing for a new ensemble performance. Beneath the headlines about exploratory talks and record highs is a deeper story about supply chains, national strategy, and a former laggard that suddenly finds itself back on center stage.
Everspin (MRAM, $41.46)
Chandler, AZ’s Everspin’s (MRAM) new $40 million defense pact reads less like a routine semiconductor contract and more like a carefully scripted act in Washington’s ongoing bid to onshore critical tech—with an Arizona memory specialist unexpectedly cast in a leading role.
PACS Group, Inc. (PACS, $41.30, +0.71%)
PACS Group, Inc. is giving Wall Street a reason to smile. With roots in Salt Lake City and a listing on the New York Stock Exchange under the ticker PACS, the company is attracting investor attention. Its stock is rallying today, while maintaining solid gains over the year despite periods of volatility. With roots in Salt Lake City and a listing on the New York Stock Exchange under the ticker PACS, the company is attracting investor attention.
Its stock is rallying today, while maintaining solid gains over the year despite periods of volatility.. Although Salt Lake City is better known for powder snow and tech start-ups than post-acute care roll-ups, PACS Group is quietly rewriting that narrative. Listed on the New York Stock Exchange, the post-acute and skilled-nursing operator has emerged as one of the healthcare sector’s more intriguing growth stories, combining Mountain West pragmatism with Wall Street ambitions. Its latest first-quarter report reinforced this momentum, as management delivered stronger revenue and higher earnings than many analysts had anticipated. In an industry often described in muted tones, reimbursement schedules and occupancy rates rarely inspire excitement. Nevertheless, PACS has managed to turn solid execution into something close to market buzz.
BuzzFeed, Inc. (BZFD, $1.31)
BuzzFeed, Inc. (NASDAQ: BZFD) has entered into a transaction agreement with Allen Family Digital, LLC, an affiliate of Byron Allen’s family office, that would see Allen invest $120 million for a majority stake in the once high-flying digital media pioneer. Under the deal, Allen’s vehicle will purchase 40 million shares at $3.00 apiece, giving it roughly 52% of BuzzFeed’s outstanding shares when the transaction closes.
Ouster, Inc. (OUST, $34.17, +26.09%)
Ouster, Inc. (Nasdaq: OUST), a leader in sensing and perception for Physical AI, announced today its new Rev8 OS family of digital lidar sensors are qualified to run on the NVIDIA DRIVE Hyperion platform for accelerating development and deployment of level 4 autonomous vehicles.
The Sources
- S&P 500 rises to another record on the back of tech even as majority of stocks close lowercnbc
Live updates on tech-led gains amid mixed breadth. - Stock Market Today: S&P 500, Nasdaq Set New Records as Tech Ralliesinvestopedia
Coverage of index records and tech momentum. - Dow slides, S&P 500 and Nasdaq rise as PPI inflation data comes in hotfinance.yahoo
Details on inflation data impact and split performance. - S&P 500 holds near record highs as tech boost offsets hot inflation datareuters
Reuters take on futures and inflation offset. - Stock Market Today (May 13, 2026): Nasdaq, S&P 500 rises despite inflationthestreet
Daily updates with inflation context. - United States Stock Market Index – Quote – Charttradingeconomics
Real-time index data and charts. - Sizzling semiconductor trade at risk of coolingreuters
Sector-specific analysis on semis. - May 2026 Market Insightscommunityamerica
Monthly macro commentary. - Market Commentary – May 2026townebank
Broader market outlook. - US Stock Market Today | Dow Jones | Nasdaq Live economictimes
Additional live coverage tying in PPI and geopolitics.
Stay Updated with Vista Partners
Subscribe to receive market insights, investing ideas, and the latest updates directly in your inbox.
